Pliant’s PLN-101325 Improves Muscle Function in Preclinical Models
Pliant Therapeutics said it plans to ask the U.S. Food and Drug Administration (FDA) for permission to begin clinical testing of PLN-101325, its experimental therapy for muscular dystrophy, by the end of this year. In preclinical studies involving cell and animal models — the results of which were presented…